Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mode of action study of QBW251 (Icenticaftor) in COPD
2019-000325-49Phase 2Suspended
- Sponsor
- Novartis
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Icenticaftor with Placebo (2 arms). Primary endpoint: Change from baseline in fibrinogen plasma concentration. Started Apr 2020; status: suspended.
02
Drugs
Icenticaftor
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2019-000325-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000325-49.